Tofacitinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tofacitinib and local guidelines before prescribing.
Mechanism
JAK inhibitor.
Uses
Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infections including herpes zoster, raised lipids, cytopenias, VTE, MACE, malignancy.
Interactions
CYP3A4 inhibitors and inducers; other immunosuppressants.
Contraindications and cautions
Active infection, severe hepatic impairment, VTE
Monitoring
FBC, LFT, lipids
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in severe renal impairment
Overdose and reversal
Supportive
Special advice
MHRA caution in those over 65, smokers and VTE or cardiovascular risk; check lipids.
More from the textbook: uses, cautions and other points
- Tofacitinib , upadacitinib , filgotinib | JAK inhibitors (oral) | Fast acting; MHRA - increased risk of VTE , major cardiovascular events, cancer and serious infection: avoid in people over 65, smokers and those with cardiovascular or cancer risk unless no alternative; shingles (vaccinate); raised lipids; teratogenic
Gastroenterology: Anatomy Physiology Pharmacology - Tofacitinib / filgotinib / upadacitinib | Oral JAK inhibitors; MHRA caution over 65, smokers, CV or cancer risk; VTE; shingles; avoid in pregnancy.
Gastroenterology: Inflammatory Bowel Disease - JAK (small molecules) | Tofacitinib, baricitinib, upadacitinib, filgotinib | RA, psoriatic arthritis, axial SpA — caution over 65s and smokers (MHRA)
Rheumatology Anatomy Physiology Pharmacology - JAK inhibitors (tofacitinib, upadacitinib) - with MHRA cautions.
Rheumatology: Inflammatory arthritis - Tofacitinib / upadacitinib | JAK inhibitors; VTE, cardiovascular and cancer risk (MHRA); shingles.
Gastroenterology: Anatomy Physiology Pharmacology - Tofacitinib and filgotinib (UC), upadacitinib (UC and Crohn's).
Gastroenterology: Inflammatory Bowel Disease - Oral targeted synthetic DMARDs - tofacitinib, baricitinib, upadacitinib, filgotinib - block Janus kinase signalling (many cytokines at once).
Rheumatology: assessment, investigations and drugs - Major cardiovascular events and malignancy (ORAL Surveillance trial with tofacitinib).
Rheumatology: assessment, investigations and drugs
Where it is discussed in the book
- Gastroenterology: Anatomy Physiology Pharmacology (2 mentions)
- Gastroenterology: Inflammatory Bowel Disease (2 mentions)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (2 mentions)
- Rheumatology: Inflammatory arthritis (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (1 mention)
- Clinical Immunology: Immune system basics and immunological investigations (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (2 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)